Therapeutic monoclonal antibodies (mAbs) targeting tumor necrosis factor alpha (TNFα) have high efficacy in treating TNFα‐related immunological diseases such as ankylosing spondylitis (AS), rheumatoid arthritis (AR), and skin diseases as psoriasis arthritis (PSA), as well as Chron's disease (CD) and ulcers colitis (UC) affecting gastrointestinal apparatus. The gene discussed is TNF; the disease is ankylosing spondylitis.